Wallace Advisory Group LLC Has $1 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Wallace Advisory Group LLC lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 8.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,641 shares of the company’s stock after purchasing an additional 930 shares during the quarter. Wallace Advisory Group LLC’s holdings in Novo Nordisk A/S were worth $1,001,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Natixis Advisors LLC increased its stake in shares of Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares during the last quarter. Norman Fields Gottscho Capital Management LLC boosted its holdings in shares of Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after buying an additional 19,870 shares during the period. Versant Capital Management Inc bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth $86,000. Zions Bancorporation N.A. boosted its holdings in shares of Novo Nordisk A/S by 57.0% during the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after buying an additional 6,726 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Novo Nordisk A/S by 14.8% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after buying an additional 37,346 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 2.1 %

Shares of NVO opened at $84.43 on Tuesday. Novo Nordisk A/S has a 1 year low of $81.50 and a 1 year high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a 50 day simple moving average of $99.84 and a 200-day simple moving average of $118.61. The stock has a market cap of $378.88 billion, a PE ratio of 27.32, a PEG ratio of 1.37 and a beta of 0.45.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on NVO. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.